Results 221 to 230 of about 150,672 (260)
Some of the next articles are maybe not open access.
Surgical Oncology Clinics of North America, 2007
Therapeutic cancer vaccines target the cellular arm of the immune system to initiate a cytotoxic T-lymphocyte response against tumor-associated antigens. Immunotherapy offers one of the few therapeutic options that reproducibly leads to a subset of patients with long-term remissions (seemingly cures) of widely metastatic disease.
Lilah F, Morris, Antoni, Ribas
openaire +2 more sources
Therapeutic cancer vaccines target the cellular arm of the immune system to initiate a cytotoxic T-lymphocyte response against tumor-associated antigens. Immunotherapy offers one of the few therapeutic options that reproducibly leads to a subset of patients with long-term remissions (seemingly cures) of widely metastatic disease.
Lilah F, Morris, Antoni, Ribas
openaire +2 more sources
Current Opinion in Pharmacology, 2019
Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade.
Calvo Tardon, Marta +4 more
openaire +4 more sources
Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade.
Calvo Tardon, Marta +4 more
openaire +4 more sources
Vaccines in the treatment of cancer
American Journal of Health-System Pharmacy, 1995The development of vaccines for treating cancer is discussed. The central hypothesis behind active specific immunotherapy for cancer is that tumor cells express unique antigens that tell the immune system that something about these cells is foreign. A vaccine is a way of delivering an antigen to the immune system such that immune cells recognize the ...
openaire +2 more sources
Cancer Investigation, 2002
The revelation that immune cytolytic and helper T-cells recognize intracellularly degraded peptides processed via the proteosome apparatus, inserted into the endoplasmic reticulum and transported to the surface for association with major histocompatibility locus (MHC) molecules on specialized antigen-presenting cells has revolutionized the cancer ...
openaire +2 more sources
The revelation that immune cytolytic and helper T-cells recognize intracellularly degraded peptides processed via the proteosome apparatus, inserted into the endoplasmic reticulum and transported to the surface for association with major histocompatibility locus (MHC) molecules on specialized antigen-presenting cells has revolutionized the cancer ...
openaire +2 more sources
A vaccine for colorectral cancer
Trends in Immunology, 2001Colorectal cancer is one of the four most prevalent cancers worldwide. It is estimated that in the USA this year, 135 400 people will be diagnosed with and 56 700 people will die from this disease. Life expectancy for stage IV disease, which might affect as many as 50 000 individuals in the USA this year, is seven and a half months.At the 37th Annual ...
openaire +2 more sources
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Nature Reviews Clinical Oncology, 2022John Haanen +2 more
exaly
Metal-based nano-vaccines for cancer immunotherapy
Coordination Chemistry Reviews, 2022Yumiao Zhang, Jiexin Li
exaly